➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Baxter
Dow
McKinsey

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,470,367


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,470,367
Title:Oral drug delivery system
Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating comprising water insoluble polymer(s) and leachable component(s) is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
Inventor(s): Bhalachandra Dharmadhikari; Nitin (Mumbai, IN), Rupsinh Zala; Yashoraj (Mumbai, IN), Singh; Amarjit (Mumbai, IN)
Assignee: Sun Pharma Advanced Research Company Ltd. (Andheri (E), Mumbai, unknown)
Application Number:11/946,575
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Compound;

Drugs Protected by US Patent 8,470,367

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Tripoint ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,470,367

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India987/MUM/2003Sep 19, 2003

International Family Members for US Patent 8,470,367

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 200603602 ⤷  Free Forever Trial
Austria 551051 ⤷  Free Forever Trial
Australia 2004283565 ⤷  Free Forever Trial
Australia 2011200881 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Johnson and Johnson
Merck
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.